title: Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
authors.forename: Derek
authors.initials: D
authors.lastname: Weycker
authors.forename: Richard L
authors.initials: RL
authors.lastname: Barron
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects*; D006760:Hospitalization; D006801:Humans; D007239:Infections / Q000628:therapy*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012107:Research Design; D012306:Risk
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim